Clinical Trial Update: Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients [Phase 1]

View source ↗

Summary

Phase 1 assessment of biodistribution and safety of the radiotracer 123-I MZINT in healthy subjects and Parkinson's disease patients; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• MZINT (I-123) (MZINT)

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Parkinson Disease | Phase 1 | Status: TERMINATED